Observed Signal · Oct 2, 2026 · Market Signal · Source: Johnson & Johnson · Impact: 4/5
Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy
Revolutionary IL-23R targeted oral peptide delivers sustained skin clearance and a favorable safety profile in patients with psoriasis affecting sensitive, highly visible areas of the body. 60% of patients with scalp psoriasis and 89% with genital psoriasis achieved site-specific complete skin clearance at Week 112.
Track Johnson & Johnson Signals & Market Shifts in Real-Time
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your free Explorer workspace to monitor these entities.
Connected Companies & Entities
1 Entity mappedRelated Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study
Topline results show TREMFYA met the primary and major secondary endpoints of axial involvement in PsA - including spinal pain and stiffness - and demonstrated significant improvement in MRI-confirmed inflammation. First-ever study to use objective MRI assessments to confirm presence of axial involvement and demonstrate axial inflammation reduction in PsA.
A behind-the-scenes look at how Johnson & Johnson manufactures and delivers CAR-T cell therapy for multiple myeloma
Transforming cancer patients’ own cells into a targeted treatment is a complex and nuanced process. Jessica Torfs, director of Global CAR-T Supply Chain at Johnson & Johnson, explains what it takes to deliver this cutting-edge personalized therapy.
New overall survival data and treatment experience improvements reinforce the impact of RYBREVANT® (amivantamab-vmjw)-based regimens in EGFR-mutated lung cancer at WCLC 2026
Presidential Symposium to feature final overall survival results for first-line RYBREVANT plus chemotherapy in EGFR exon 20 insertion-mutated NSCLC. Additional findings show low rates of key treatment-related events with subcutaneous RYBREVANT FASPRO™ and prophylactic strategies.
Track Real-Time Market Signals & Shifts
Set up custom watchlists to receive automated, evidence-grounded executive digests whenever material signals or shifts occur across your tracked landscape.